MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering
Summary
"Novel modalities like cell and gene therapies offer tremendous potential for bringing new curative treatments to patients,” said Sebastian Arana, Head of Process Solutions, Life Science business of Merck KGaA, Darmstadt, Germany. The addition of Mirus Bio’s leading transfection reagents strengthens MilliporeSigmas upstream portfolio and allows for an integrated viral vector manufacturing offering. The Life Science business of Merck KGaA, Darmstadt, Germany provides solutions for every step of the viral vector manufacturing process to advance cell and gene therapies from preclinical through commercial production. Additionally, the company offers contract testing and comprehensive CDMO services for viral vector manufacturing, leveraging three decades of experience supporting cell and gene therapies. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere.
Classifications
AskAI Classifications
LabelsLinked Companies
